S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Wall Street adds more to its big January after strong week
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Wall Street adds more to its big January after strong week
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Wall Street adds more to its big January after strong week
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Wall Street adds more to its big January after strong week
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
NASDAQ:GLMD

Galmed Pharmaceuticals - GLMD Stock Forecast, Price & News

$0.65
-0.02 (-2.98%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.65
$0.72
50-Day Range
$0.29
$0.90
52-Week Range
$0.29
$1.84
Volume
52,695 shs
Average Volume
152,640 shs
Market Capitalization
$16.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Galmed Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
667.9% Upside
$5.00 Price Target
Short Interest
Healthy
0.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Galmed Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.73) to ($0.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

477th out of 1,055 stocks

Pharmaceutical Preparations Industry

231st out of 519 stocks


GLMD stock logo

About Galmed Pharmaceuticals (NASDAQ:GLMD) Stock

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Stock News Headlines

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Galmed Pharmaceuticals Shares Down 16%
Galmed Pharmaceuticals's Earnings Outlook
See More Headlines
Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Company Calendar

Last Earnings
11/16/2022
Today
1/28/2023
Next Earnings (Estimated)
5/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLMD
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+667.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-32,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.22 per share

Miscellaneous

Free Float
20,121,000
Market Cap
$16.34 million
Optionable
Optionable
Beta
1.11

Key Executives

  • Allen Baharaff
    Chairman, President & Chief Executive Officer
  • Guy Nehemya
    Chief Operating & Data Protection Officer
  • Doron Cohen
    Chief Financial Officer
  • Liat Hayardeny
    Chief Scientific Officer
  • Neta Tobis
    Director-Clinical Affairs













GLMD Stock - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View GLMD analyst ratings
or view top-rated stocks.

What is Galmed Pharmaceuticals' stock price forecast for 2023?

5 Wall Street analysts have issued 1 year price objectives for Galmed Pharmaceuticals' shares. Their GLMD share price forecasts range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 667.9% from the stock's current price.
View analysts price targets for GLMD
or view top-rated stocks among Wall Street analysts.

How have GLMD shares performed in 2023?

Galmed Pharmaceuticals' stock was trading at $0.50 on January 1st, 2023. Since then, GLMD stock has increased by 30.2% and is now trading at $0.6511.
View the best growth stocks for 2023 here
.

When is Galmed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our GLMD earnings forecast
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) posted its earnings results on Wednesday, November, 16th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.06.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $0.65.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $16.34 million. The biopharmaceutical company earns $-32,470,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for the company is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447.

This page (NASDAQ:GLMD) was last updated on 1/28/2023 by MarketBeat.com Staff